| 摘要 |
A recombinant, adenoviral vector (I) which is capable of in vivo autoreplication only after part deletion of the E1 region, and which can produce no more infectious, adenoviral particles, is new. Independent claims are also included for the following: (1) preparation of (I); and (2) a medicament for gene therapy comprising (I). |
